Cargando…

Portal Vein Thrombosis in Unresectable Hcc Cases: a Single Center Study of Prognostic Factors and Management in 140 Patients

OBJECTIVE: Hepatocellular carcinoma with portal vein thrombosis is considered a relative contraindication for transarterial chemoembolization (TACE). The aim of our study was to evaluate the prognostic factors and management in patients with hepatocellular carcinoma with portal vein thrombosis (PVT)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Abdelmaksoud, Ahmed Hosni, Mandooh, Safaa, Nabeel, Mohamed Mahmoud, Elbaz, Tamer Mahmoud, Shousha, Hend Ibrahim, Monier, Ashraf, Elattar, Inas Anwar, Abdelaziz, Ashraf Omar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	West Asia Organization for Cancer Prevention 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5563098/ https://www.ncbi.nlm.nih.gov/pubmed/28240515 http://dx.doi.org/10.22034/APJCP.2017.18.1.183

Ejemplares similares

Transarterial Chemoembolization Combined with Either Radiofrequency or Microwave Ablation in Management of Hepatocellular Carcinoma
por: Abdelaziz, Ashraf Omar, et al.
Publicado: (2017)

Robotic-Assisted versus Conventional Laparoscopic Approach for Rectal Cancer Surgery, First Egyptian Academic Center Experience, RCT
por: Debakey, Yasser, et al.
Publicado: (2018)

Seven gene signature explores the impact of DAAs on the appearance of hepatocellular carcinoma in HCV infected patients
por: Dawood, Reham M., et al.
Publicado: (2022)

Assessment of circulating levels of microRNA-326, microRNA-424, and microRNA-511 as biomarkers for hepatocellular carcinoma in Egyptians
por: Youssef, Samar Samir, et al.
Publicado: (2022)

Macroscopic Portal Vein Thrombosis in HCC Patients
por: Akkiz, Hikmet, et al.
Publicado: (2018)

Virtual Screening and Biological Evaluation of Potential PD-1/PD-L1 Immune Checkpoint Inhibitors as Anti-Hepatocellular Carcinoma Agents
por: Kamal, Monica A., et al.
Publicado: (2023)

Chemotherapy combined with radiotherapy can benefit more unresectable HCC patients with portal and/or hepatic vein invasion: a retrospective analysis of the SEER database
por: Qiu, Xiaotong, et al.
Publicado: (2023)

Yttrium‐90 Radioembolization for the Treatment of Solitary, Unresectable HCC: The LEGACY Study
por: Salem, Riad, et al.
Publicado: (2021)

Hepatectomy After Conversion Therapy for Initially Unresectable HCC: What is the Difference?
por: Luo, Laihui, et al.
Publicado: (2022)

Stereotactic Percutaneous Electrochemotherapy as Primary Approach for Unresectable Large HCC at the Hepatic Hilum
por: Luerken, L., et al.
Publicado: (2021)

Combination Therapy of Sorafenib and TACE for Unresectable HCC: A Systematic Review and Meta-Analysis
por: Liu, Lei, et al.
Publicado: (2014)

Effectiveness and tolerability of camrelizumab combined with molecular targeted therapy for patients with unresectable or advanced HCC
por: Li, Ting, et al.
Publicado: (2023)

Tumor Regression in HCC Patient with Portal Vein Tumor Thrombosis after Intraportal Radiofrequency Thermal Ablation
por: Mizandari, Malkhaz, et al.
Publicado: (2016)

Yttrium-90 trans-arterial radioembolization in advanced-stage HCC: The impact of portal vein thrombosis on survival
por: Somma, Francesco, et al.
Publicado: (2019)

Catalpol inhibits the proliferation, migration and metastasis of HCC cells by regulating miR-140-5p expression
por: Wu, Linsheng, et al.
Publicado: (2021)

Psychometric validation of the EORTC QLQ-HCC18 in patients with previously treated unresectable hepatocellular carcinoma
por: Serrano, Daniel, et al.
Publicado: (2021)

Knowledge, awareness, and perception of digital dentistry among Egyptian dentists: a cross-sectional study
por: Hall, Mohamed Ashraf, et al.
Publicado: (2023)

External Radiation versus Internal Radiation for Patients with Advanced Unresectable HCC -A SEER Based Study
por: Wang, Xuan, et al.
Publicado: (2019)

Transarterial Chemoembolization in Unresectable Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: A Tertiary Care Center Experience
por: Patidar, Yashwant, et al.
Publicado: (2021)

Hepatic arterial infusion of oxaliplatin plus raltitrexed in unresectable hepatocellular carcinoma with or without portal vein tumour thrombosis
por: Chen, Shiguang, et al.
Publicado: (2022)

Sorafenib plus tegafur–uracil (UFT) versus sorafenib as first line systemic treatment for patients with advanced stage HCC: a Phase II trial (ESLC01 study)
por: Azim, Hamdy A, et al.
Publicado: (2018)

Elevated plasma homocysteine is positively associated with age independent of C677T mutation of the methylenetetrahydrofolate reductase gene in selected Egyptian subjects
por: El-Sammak, Mohamed, et al.
Publicado: (2004)

Extracorporeal Hepatic Resection and Autotransplantation Using Temporary Portocaval Shunt Provides an Improved Solution for Conventionally Unresectable HCC
por: Wen, Pei-Hung, et al.
Publicado: (2013)

Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan
por: Kobayashi, Masahiro, et al.
Publicado: (2019)

A Real-World Comparative Analysis of Lenvatinib and Sorafenib as a Salvage Therapy for Transarterial Treatments in Unresectable HCC
por: Lee, Jaejun, et al.
Publicado: (2020)

Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study
por: Fu, Zhigang, et al.
Publicado: (2021)

Low Baseline CXCL9 Predicts Early Progressive Disease in Unresectable HCC with Atezolizumab Plus Bevacizumab Treatment
por: Hosoda, Shunichi, et al.
Publicado: (2022)

Does first‐line treatment have prognostic impact for unresectable HCC?—Atezolizumab plus bevacizumab versus lenvatinib
por: Hiraoka, Atsushi, et al.
Publicado: (2022)

Long‐term antitumor effect of lenvatinib on unresectable hepatocellular carcinoma with portal vein invasion
por: Takeda, Haruhiko, et al.
Publicado: (2019)

Role of CT in Assessment of Unresectable Wilms' Tumor Response after Preoperative Chemotherapy in Pediatrics
por: Refaie, Huda, et al.
Publicado: (2008)

TIPS improves outcomes in patients with HCC and symptomatic portal hypertension: a multi-institution experience
por: Yan, Huzheng, et al.
Publicado: (2022)

Bicyclic 6 + 6 systems: the chemistry of pyrimido[4,5-d]pyrimidines and pyrimido[5,4-d]pyrimidines
por: Monier, M., et al.
Publicado: (2019)

Advances in the chemical and biological diversity of heterocyclic systems incorporating pyrimido[1,6-a]pyrimidine and pyrimido[1,6-c]pyrimidine scaffolds
por: Elattar, Khaled M., et al.
Publicado: (2020)

Comparing the long-term efficacy of standard and combined minimally invasive procedures for unresectable HCC: a mixed treatment comparison
por: Zhao, Jianghai, et al.
Publicado: (2016)

Efficacy and safety of TACE combined with lenvatinib and PD‐1 inhibitors for unresectable recurrent HCC: A multicenter, retrospective study
por: Wang, Wei‐Jun, et al.
Publicado: (2023)

Contrast-enhanced ultrasound for the characterization of portal vein thrombosis vs tumor-in-vein in HCC patients: a systematic review and meta-analysis
por: Chen, Jifan, et al.
Publicado: (2020)

Hepatic portal vein gas detected by point of care ultrasound
por: Bitar, Zouheir Ibrahim, et al.
Publicado: (2021)

Intra-arterial ethanol embolization augments response to TACE for treatment of HCC with portal venous tumor thrombus
por: Yang, Biao, et al.
Publicado: (2018)

Short-term and long-term outcomes of liver resection for HCC patients with portal vein tumor thrombus
por: Huo, Lei, et al.
Publicado: (2019)

Efficacy evaluation of the combination therapy of sorafenib and transarterial chemoembolization for unresectable HCC: a systematic review and meta-analysis of comparative studies
por: Li, Huichen, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_5quk5v0sj22gnc4tmtu2tte878